Findings

What do systematic reviews say?

26 questions · 26 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 7.7%GRADE not reported 0 · 0%Very low 7 · 26.9%Low 11 · 42.3%Moderate 3 · 11.5%High 3 · 11.5%

Pazopanib plus lapatinib vs lapatinib

Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer

Pazopanib plus lapatinib showed no clear difference in serious adverse events compared with lapatinib (low certainty).

1 finding from 1 review

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
RR 1.45 [0.94, 2.26]
1 study · 152 participants
Low

Pazopanib plus lapatinib vs lapatinib

Economic evaluation ‐ not measured · women with persistent, recurrent, or metastatic cervical cancer

The review found no eligible studies for this question.

1 finding from 1 review

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sorafenib vs pazopanib (targeted agent versus targeted agent)

Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

Sorafenib probably leads to higher progression‐free survival (absolute effect size estimates based on… compared with pazopanib (targeted agent versus targeted agent) (moderate certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
HR 1.92 [1.74, 2.11]
1 study · 377 participants
Moderate

Sorafenib vs pazopanib (targeted agent versus targeted agent)

Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

Sorafenib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with pazopanib (targeted agent versus targeted agent) (low certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
HR 1.22 [0.91, 1.64]
1 study · 377 participants
Low

Sorafenib vs pazopanib (targeted agent versus targeted agent)

Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

It is very uncertain whether sorafenib changes serious adverse events (Grade 3 or 4) compared with pazopanib (targeted agent versus targeted agent) (very low certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
RR 0.92 [0.78, 1.09]
1 study · 366 participants
Very low

Sorafenib vs pazopanib (targeted agent versus targeted agent)

Health‐related quality of life (mean change value) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 267 participants
Low